Nutrinia Reveals $30 Million Series D Financing To Fund Scientific Advancement Of Lead Item

RAMAT-GAN, Israel MORRISTOWN, NJ–( BUSINESS WIRE)– Nutrinia,.
Ltd. (” Nutrinia”), a business establishing a proprietary oral.
formulation of insulin for digestive tract malabsorption in preterm babies.
and Short Bowel Syndrome (SBS) in babies, today announced the closing.
of a $30 million Series D funding to money two pivotal trials for.
registration. TPG Biotech, the life science endeavor financial investment arm of.
leading global alternative asset firm TPG, led the investment, signed up with by.
HIG. BioHealth Partners and WuXi Health care Ventures, along with.
existing financiers consisting of OrbiMed, Pontifax and others.

Nutrinia will use the proceeds to initiate 2 pivotal trials for.
registration in separate indicators connected to velocity of gut.
maturation and adaptation: digestive malabsorption in preterm babies.
born between 26 and 32 weeks’ gestational age, and infants with SBS who.
are under 12 months old.

” I’m delighted enjoy to welcome TPG Biotech, HIG. BioHealth Partners and WuXi.
Healthcare Ventures into Nutrinia at this amazing time for the.
business,” stated Miki Olshansky, Nutrinia’s Chief Executive Officer. “We.
are starting 2 trials in the US and Europe that will provide robust.
information as to the security and effectiveness of our proprietary oral formulation.
of insulin, and if effective, offer a direct course to registration.
These are orphan signs that affect delicate populations with high.
levels of unmet medical need.”.

” The biological rationale for Nutrinia’s product is strong and the.
company’s preclinical information and outcomes of several previous medical.
trials are compelling,” stated Eran Nadav, PhD, Partner and Managing.
Director at TPG Biotech. “We believe that neonatology, and specifically.
the NICU, are locations that should have specific therapeutic advancement.
focus, and we are delighted to support Nutrinia’s efforts.”.

With this financial investment, Dr. Nadav will join Nutrinia’s Board of Directors,.
as will Aaron Davidson, Co-head and Managing Director of HIG.
BioHealth Partners.

About Nutrinia, Ltd.

. Nutrinia, Ltd. is a medical phase biotechnology company focused on.
establishing an exclusive oral solution of insulin for.
gastrointestinal indicators in infants. Insulin has been revealed to.
induce a receptor-mediated action leading to gut maturation and.
adaptation, crucial in preterm babies with intestinal malabsorption.
and babies likewise affected by Short Bowel Syndrome. There are no.
approved therapies for either of these orphan conditions.

Nutrinia’s distinct oral formula of insulin is in your area acting, and.
stable at room temperature level, rapidly liquifying into saline, formula or.
breast milk, and created for administration through the plastic tubing.
used in enteral feeding in addition to simply orally. The Business has shown.
efficacy and safety in animal studies and numerous human medical.
trials. Nutrinia is headquartered in Ramat-Gan, Israel, with its US.
operations based out of Morristown, NJ.

For additional details, check out www.nutrinia.com.

Tags:

Comments are closed.